- Regenerative Medicine
- Dermatology & Devices
- Topicals & Pharmacy
Autologous Platelet Rich Plasma and Progenitor Stem Cell Biologics has become a standard of care in modern medicine. With 20 + years of innovation and development, EmCyte Corporation® is widely recognized as the standard bearer, with a product portfolio that meets the highest achievable performance outcomes in point of care regenerative medicine. EmCyte biologics has been successfully used in <2 million patients, making it the most widely used single platform in the world. Join the family of clinical effectiveness and appreciable outcomes with EmCyte Autologous Regenerative Biologics.
EmCyte has remained committed to innovation that truly makes a clinical difference. Emcyte’s highly versatile platform offers providers a choice of treatment types using the following devices:
To learn which options are best for your practice, contact me for a consult.
Alpha-2-macroglobulin (A2M) is found in our plasma. This molecule is a powerful inhibitor of cartilage catabolic factors that slow cartilage breakdown and prevent cartilage loss.
A2M signals the destructive cells to stop their degenerative effect. This inhibiting factor makes A2M a viable option for biologic treatments, promoting increased strength and improving overall function over a 4-6 week period.
The Progenikine® adipose concentrating system is a powerful, FDA-cleared device that offers a clean adipose concentrate sample devoid of oil and tumescent infranatant.
Designed to improve performance outcomes, PureBMC® allows physicians to more accurately collect high therapeutic cell concentrates with low red blood cell content. Hematopoietic stem cells (CD34+), total nucleated cell (TNC), mesenchymal stem cell (CFU-F) and platelet isolation is perfected in the PureBMC® system.
Using a specialized cell isolation technique, PureBMC® provides more than 9X cell concentration in 7ml of PureBMC®. Preparation times are less than 10 minutes at the point of care. With careful attention to the details of gradient cell isolation, PureBMC® is a viable choice for a low hematocrit and high yielding bone marrow cell concentrate product.